BFM
SGMT icon

Boothbay Fund Management’s Sagimet Biosciences SGMT Stock Holding History

Boothbay Fund Management’s Portfolio SGMT Stock Details SGMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.59M Buy
+464,095
New +$3.16M 0.05% 451
2025
Q2 		– Sell
-12,518
Closed -$40.8K – 1734
2025
Q1 		$40.8K Hold
12,518
– – ﹤0.01% 1298
2024
Q4 		$56.3K Sell
12,518
-102,433
-89% -$519K ﹤0.01% 1343
2024
Q3 		$318K Sell
114,951
-7,414
-6% -$22.9K 0.01% 1195
2024
Q2 		$418K Hold
122,365
– – 0.01% 1050
2024
Q1 		$663K Buy
+122,365
New +$879K 0.01% 902

Other funds holding SGMT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return

Boothbay Fund Management's SGMT Position: Q2 2026 in Review

Boothbay Fund Management opened a new position in Sagimet Biosciences (SGMT) in Q2 2026: 464,095 shares worth $3.59M. The stake represents 0.05% of the portfolio and ranks #451 among its holdings. This is a return to the name: Boothbay Fund Management previously reported a position in SGMT as recently as Q1 2025.

Boothbay Fund Management first reported a position in SGMT in Q1 2024 and has held it in 6 quarters since. 122 funds tracked by Wall St. Rank hold SGMT as of Q2 2026.

  • Boothbay Fund Management held 464,095 shares of Sagimet Biosciences worth $3.59M as of Q2 2026.
  • Sagimet Biosciences was a new Boothbay Fund Management position in Q2 2026.
  • Sagimet Biosciences made up 0.05% of Boothbay Fund Management's portfolio in Q2 2026, its #451 holding.
  • Boothbay Fund Management first reported a position in Sagimet Biosciences in Q1 2024 and has held it in 6 quarters since.
  • 122 funds tracked by Wall St. Rank held Sagimet Biosciences as of Q2 2026.

Based on Boothbay Fund Management's 13F filing for Q2 2026, filed 14 Aug 2026.